Explainable AI helps families manage obesity in kids and young adults with diabetes or asthma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm feasibility study of the Adhera Caring Digital Program for Obesity (ACDP-O). The program blends personalized education, wearable data, psychometric monitoring, and explainable AI to support mental well-being, quality of life, and adherence to healthy lifestyle behaviors in families. Participants include adolescents and young adults with overweight/obesity and chronic conditions (Type 1 diabetes or asthma) and a normal-weight comparison group, enrolled with caregiver involvement. The study uses baseline, 90-day intervention, and post-intervention assessments to evaluate feasibility, acceptability, engagement, usability, caregiver burden, and disease-specific outcomes. Primary aim is to determine feasibility and preliminary signals of effectiveness for future trials.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult caregiver (aged 18 years or older) of an adolescent or young adult aged 12 to 21 years diagnosed with Type 1 Diabetes (T1D) or asthma.
* The caregiver is actively involved in the management of the adolescent's or young adult's condition.
* The adolescent or young adult must meet one of the following criteria:
* T1D and normal weight (BMI between the 10th and 85th percentile), or
* T1D and overweight/obesity (BMI ≥85th percentile), or
* Asthma and overweight/obesity (BMI ≥85th percentile).
* Willingness to participate in the Adhera Caring Digital Program-Obesity (ACDP-O).
* Access to a smartphone or internet-enabled device compatible with the study application.
* Willingness to provide self-reported information regarding the adolescent's or young adult's health status, including disease-related and anthropometric measures.
* For caregivers of participants with T1D, willingness to share continuous glucose monitoring (CGM) information.

Exclusion Criteria:

* Severe psychiatric or cognitive conditions that would interfere with participation in the digital intervention.
* Current participation in another obesity- or chronic disease-related digital health intervention study.
* Inability or unwillingness to comply with study procedures.
* Refusal or inability to provide informed consent.

Where it's running

• Adhera Health (Virtual Participation)
  Seville, Spain Recruiting

Study contacts

• Study coordinator: Luis Fernández Luque, PhD
• Email: luis@adherahealth.com
• Phone: +1 (831) 345-5357

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Real-Time Glucose Monitoring in Newly Diagnosed Type 2 Diabetes

  This study tests whether real-time glucose monitoring helps people with newly diagnosed type 2 diabetes manage glucose better than traditional finger-prick testing.

  Recruiting at 2 sites Bogomolets National Medical University · Kyiv and 2 other locations · NCT07690163

• Near-sensor insulin delivery with CGM in people with type 1 diabetes

  A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.

  Recruiting Early Phase 1 ClinSurge Research · Toronto, Ontario · NCT07655076

• Hydration Support to Help GLP-1 Therapy Side Effects

  This 17-week program tests whether boosting hydration in people starting GLP-1 receptor agonist therapy can lessen side effects and help people continue treatment.

  Recruiting State University of New York at Buffalo · Buffalo, New York · NCT07641361

• Eating patterns before, during, and after obesity medication in adults with obesity

  This study will see how eating habits change over 18 months for adults with obesity who are taking obesity medications as part of routine care.

  Recruiting University College Dublin · Dublin · NCT07636395

• Tirzepatide added to an automated insulin delivery system to help adults with type 1 diabetes manage blood sugar

  This study tests whether once-weekly tirzepatide can help adults with type 1 diabetes use their insulin pumps more easily, possibly reducing the need to count carbohydrates at meals.

  Recruiting Phase 2/3 McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec and 3 other locations · NCT07284511

• CNP-103 treatment for adolescents and young adults recently diagnosed with stage 3 type 1 diabetes

  This trial will test whether multiple doses of CNP-103, compared with placebo, help people ages 12–35 who were diagnosed with stage 3 type 1 diabetes within the past 6 months.

  Recruiting at 45 sites Phase 1/2 COUR Pharmaceutical Development Company, Inc. · Tucson, Arizona and 44 other locations · NCT06783309

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.